Nanochon

Medtech · Private

3D-printed implantable cartilage repair device made from novel biomimetic nanomaterial

Claim this profile

Follows are private to you and power your alerts

Updated · nanochon.com

Sector
Medtech
Total capital
$335K
Federal grants
$335K
2 awards · 2017–2026
Rank in peer group#345 of 445
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
2
10 pending · first 2020
Rank in peer group#88 of 445

Capital timeline

20172019202120232025FEDERAL ↑EQUITY ↓Cumulative $335K$225K$110K
20172019202120232025FEDERAL ↑EQUITY ↓Cumulative $335K$225K$110K

Latest events

  • Federal grantDefense · Phase I · Three Dimensional Printed Cartilage Repair Treatment For Post Traumatic Osteoarthritis In The Knee$110K
  • Federal grantNSF · Phase I · SBIR Phase I: Development of Production-Ready 3D Printable Cartilage Repair Device for Clinical Use$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 445 peers

Line = median

Medtech · Device

  • Federal grantsBelow median
  • Granted patents#88 · top 20%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Benjamin HolmesResearcherExecutive Officer, DirectorLinked by $225K in grants as PI
  • Greg HornerDirectorNamed in SEC Form D filings
  • Kurt JacobusDirectorNamed in SEC Form D filings
  • Nathan CastroExecutive Officer, DirectorNamed in SEC Form D filings
  • Nick PachudaDirectorNamed in SEC Form D filings
  • Robert CreedenDirectorNamed in SEC Form D filings
Show all 7 people
  • Sean ChurchillDirectorNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 12
Show all 12 patent records
  • Three-dimensionally Printed Tissue Engineering Scaffolds For Tissue RegenerationNov 4, 2025 · US 12,458,499Granted
  • Implantable Scaffolds And Uses ThereofSep 30, 2021 · Application 17264224Pending
  • Three-dimensionally Printed Tissue Engineering Scaffolds For Tissue RegenerationApr 21, 2020 · US 10,624,750Granted
  • Tissue Implant And Uses ThereofApplication 63716542Pending
  • Implantable Scaffolds And Uses ThereofApplication PCTUS2019043955Pending
  • Three-dimensionally Printed Surgically Implantable Scaffolds For Facilitating Tissue RegenerationApplication 62775228Pending
  • Three dimensionally printed surgically implantable scaffolds for facilitating tissue regenerationApplication 62711667Pending
  • Three-dimensionally Printed Tissue Engineering Scaffolds For Tissue RegenerationApplication PCTUS2017045792Pending
  • Tissue Implant And Uses ThereofApplication PCTUS2025053826Pending
  • Three-dimensionally printed tissue engineering scaffolds for tissue regenerationApplication 62371805Pending
  • Surgical Tools For Implanting A Tissue ScaffoldApplication PCTUS2025015517Pending
  • Non-adhesively Affixed Tissue ScaffoldsApplication PCTUS2025015462Pending

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .